- ECONOMIC IMPACT -

Latest update: 15 September 

The global economy is forecasted to return to pre-crisis levels by the end of 2021 or early 2022. 

According to Statistics South Africa, real GDP in the nation expanded by 1.2% in Q2 2021.

6.2%

The unemployment rate in OECD nations stood at 6.2% in July 2021, down from 6.4% in June 2021.

4.5%

World economic growth is projected at 5.7% in 2021 and at 4.5% in 2022, according to HIS Markit.

Impact of Covid-19 on equity indices

- SECTOR IMPACT: PHARMA -

Latest update: 08 October

industry development

5,941

Currently, there are 5,941 clinical trials for Covid-19 and promising clinical data continues to emerge for Covid-19 vaccines. 

1,058

Trial disruption is levelling off, with 1,058 trials still disrupted and 628 pharma/biotech companies and clinical research organisations associated with disrupted trials.

Outsourcers (CROs/CMOs)

Stalled clinical trials created a work vacuum for clinical research organisations (CROs) and contract development and manufacturing organisations but disrupted trials are slowly starting to resume.


Contract manufacturing organisations (CMOs) and excess capacity contract manufacturers with secure supply lines will benefit from a short term boost in generic drugs manufacturing needed to treat Covid-19 patients.


Outsourcing partners must deal with issues surrounding a potential excess of client needs upon initiation of future trials, with guidance from regulatory agencies still pending.

Key pharma market developments

Providers


Hospitals are being forced to operate with a shortage of proper personal protection equipment, complicating the health and safety of both patients and staff.


Meanwhile, outpatient healthcare providers will have to rely on telemedicine and remote methods of treating patients which may be less effective than face-to-face patient management.


Payers


Currently, payers are experiencing pressure to reimburse intensive care unit care and eventually this could expand to include potentially expensive and unproven drugs if there is a suggestion that they might be effective in treating Covid-19.


In addition, payer plans have evolved to include reimbursement of telemedicine as providers began to rely on this service during the pandemic. Reimbursement of telemedicine is likely here to stay.

Share this article